Methods and compositions for improving endothelial cell barrier - Patents.com

By employing barrier agonist compounds to enhance endothelial cell junction proteins, the method addresses the challenge of vascular leakage in lung scaffolds, achieving improved vascular barrier function for transplantable lung tissue.

JP2024542845APending Publication Date: 2024-11-15UNITED THERAPEUTICS CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534276
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-19
Filing Date
2022-12-07
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing methods for generating transplantable lung scaffolds face significant challenges in restoring a mature and functional vascular barrier due to fluid leakage from recellularized vasculature, primarily due to the difficulty in enhancing endothelial cell-cell junctions and tight junction protein expression.

Method used

The use of barrier agonist compounds, such as forskolin and fingolimod-phosphate, to enhance the expression of endothelial cell-cell junction proteins and tight junction proteins in cultured endothelial cells, thereby strengthening the vascular barrier.

Benefits of technology

The method effectively reduces vascular leakage by increasing the expression of adherens and tight junction proteins, leading to improved vascular barrier function and potential success in transplantable lung tissue engineering.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542845000001_ABST
    Figure 2024542845000001_ABST
Patent Text Reader

Abstract

Described herein is a method and composition for use in improving endothelial cell vascular barrier.The method may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells.The improved method and composition for culturing endothelial cells may include at least one or more of the following: adenylyl cyclase activator, sphingosine-1-phosphate (S1P) receptor internalization activator, direct or indirect inducer of tight junction protein expression, and direct or indirect inducer of adherens junction protein expression.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 287,254, filed December 8, 2021, and U.S. Provisional Patent Application No. 63 / 399,494, filed August 19, 2022, the entire contents of which are incorporated herein by reference.

[0002] This application relates generally to cell cultures and more particularly, but not exclusively, to methods and compositions for improving the vascular barrier of endothelial cells and cells produced from such methods. [Background technology]

[0003] The present application relates to the use of barrier agonist compounds to enhance the vascular barrier of endothelial cells in culture.

[0004] Lung tissue engineering is a promising, yet challenging, field with the potential to provide healthy, transplantable lungs for the over 400,000 Americans who die from lung disease each year. One strategy to generate tissue engineered transplantable lungs is via a decellularization-recellularization method that uses porcine lungs as the starting scaffold. One of the greatest challenges to successful implantation of such lung scaffolds is restoring a mature, functional vascular barrier. A key component of the mature vascular barrier is the endothelial expression of tight and adherens junction proteins that help regulate the movement of fluids and molecules from the bloodstream to the underlying lung tissue.

[0005] Prevention of leakage from the recellularized vasculature of porcine lung scaffolds remains very difficult.One reason why recellularized lung scaffolds fail in functional tests (e.g., ex vivo lung perfusion) is that vascular leakage causes fluid to flow into the airways.Therefore, there is still an unmet need for methods and compositions that reduce vascular leakage of cells in cultured endothelial cells. Summary of the Invention

[0006] The present disclosure addresses the shortcomings of previously known approaches by providing methods and compositions for producing endothelial cells with enhanced vascular barriers. The methods and compositions of the present disclosure can be used to produce cultured endothelial cells with enhanced vascular barriers, characterized by reduced vascular leakage. Also provided herein are improved methods and compositions for producing lung tissue from endothelial cells with enhanced vascular barriers.

[0007] The method of producing endothelial cells can include contacting endothelial cells with at least two barrier agonist compounds.In some embodiments, the method of producing endothelial cells can further include contacting endothelial cells with at least two barrier agonist compounds during culturing.In many embodiments, the step of contacting endothelial cells with at least two barrier agonist compounds can be performed for a sufficient period of time to allow endothelial cells to strengthen the vascular barrier.In some aspects, the strengthening of vascular barrier is determined by reducing vascular leakage.

[0008] The endothelial cell of the present disclosure can be any human or non-human endothelial cell. The endothelial cell of the present disclosure can be a pulmonary endothelial cell. In some embodiments, the endothelial cell can be selected from the group consisting of human pulmonary artery endothelial cell (HPAEC) and human pulmonary microvascular endothelial cell (HMVEC). In some aspects, the method of producing endothelial cell further comprises using endothelial cell to produce transplantable lung.

[0009] The barrier agonist compounds of the present disclosure may include one or more compounds that promote increased expression of endothelial cell-cell junctions, promote increased production of cyclic adenosine monophosphate, promote increased production of adherens junction proteins (e.g., VE-cadherin), or promote increased production of tight junction proteins (e.g., ZO-1, JAM-A, claudin-5, occludin). In some preferred embodiments, the method of making endothelial cells may include contacting endothelial cells with at least two barrier agonist compounds, the at least two barrier agonist compounds including forskolin and fingolimod-phosphate. In some embodiments, the barrier agonist compounds may further include methylprednisolone. In some such embodiments of the method of making endothelial cells, forskolin may be present at a concentration of about 30 μM to about 50 μM. Preferably, forskolin may be present at a concentration of about 40 μM. In some embodiments, fingolimod-phosphate may be present at a concentration of about 5 nM to about 50 nM. Preferably, fingolimod-phosphate may be present at a concentration of about 50 nM. In some preferred embodiments, forskolin may be present at a concentration of about 40 μM and fingolimod-phosphate may be present at a concentration of about 50 nM.

[0010] Disclosed herein is an improved method for preparing lung tissue from cultured endothelial cells in cell culture medium. In some embodiments, the improvement comprises (i) contacting cultured endothelial cells with at least two barrier agonist compounds, and (ii) maintaining endothelial cells in cell culture medium for a sufficient period of time to allow the endothelial cells to strengthen the vascular barrier, wherein the strengthening of the vascular barrier is characterized by a reduction in vascular leakage. In some embodiments, the at least two barrier agonist compounds may include forskolin and fingolimod-phosphate. In some such embodiments of the improved method for preparing lung tissue from cultured endothelial cells in cell culture medium, forskolin may be present at a concentration of about 30 μM to about 50 μM. Preferably, forskolin may be present at a concentration of about 40 μM. In some embodiments, fingolimod-phosphate may be present at a concentration of about 5 nM to about 50 nM. Preferably, fingolimod-phosphate may be present at a concentration of about 50 nM. In some preferred embodiments of such improved methods, forskolin may be present at a concentration of about 40 μM and fingolimod-phosphate may be present at a concentration of about 50 nM.

[0011] The present disclosure provides a cell culture medium composition useful for producing endothelial cells.The cell culture medium composition can include at least two barrier agonist compounds.In some embodiments, the at least two barrier agonist compounds included in the cell culture medium composition of the present disclosure can include forskolin and fingolimod-phosphate.In some embodiments, the barrier agonist compounds included in the cell culture medium composition of the present disclosure can include forskolin, fingolimod-phosphate, and methylprednisolone.

[0012] The foregoing summary, as well as the following description of the drawings and detailed description, are exemplary and explanatory and are intended to provide further details of the present disclosure and are not to be construed as limiting. Other objects, advantages and novel features will become readily apparent to those skilled in the art from the following detailed description of the present disclosure. [Brief description of the drawings]

[0013] [Figure 1] Figures 1A-1B: Efficacy of barrier agonist compounds forskolin and FTY720P in increasing impedance of cultured HPAECs after 15, 48, and 120 hours of treatment with MCDB131 (Figure 1A) and HPLM (Figure 1B) culture media. [Diagram 2] 2A-B: Efficacy of the barrier agonist compound forskolin in increasing impedance of cultured HMVECs obtained from PromoCell (PC) after 15, 48, and 100 hours of treatment with MCDB131 culture medium with 0 μM, 10 μM, or 40 μM forskolin. (FIG. 2A) Normalized impedance measured by ECIS at various treatment conditions. (FIG. 2B) Raw ECIS traces obtained at various treatment conditions. [Diagram 3] 3A-B: Efficacy of the barrier agonist compound forskolin in increasing impedance of cultured HMVECs obtained from Cell Applications (CA) after 15, 48, and 100 hours of treatment with MCDB131 culture medium with 0 μM, 10 μM, or 40 μM forskolin. (FIG. 3A) Normalized impedance measured by ECIS at various treatment conditions. (FIG. 3B) Raw ECIS traces obtained at various treatment conditions. [Figure 4] 4A-B: Efficacy of the barrier agonist compound forskolin in increasing impedance of cultured HPAEC obtained from ATCC 15, 48, and 100 hours after treatment with MCDB131 culture medium with 0 μM, 40 μM, or 60 μM forskolin. (FIG. 4A) Normalized impedance measured by ECIS at various treatment conditions. (FIG. 4B) Raw ECIS traces obtained at various treatment conditions. [Diagram 5]FIG. 13 shows the efficacy of barrier agonist compounds forskolin and FTY720P in increasing impedance of cultured HPAECs after 15, 48, and 120 hours of treatment with MCDB131 culture medium with 0 μM or 40 μM forskolin and 0 nM, 5 nM, or 50 nM FTY720P. [Figure 6] Figures 6A-C: Efficacy of barrier agonist compounds forskolin and FTY720P in enhancing the vascular barrier of cultured HPAECs after 18 hours of treatment with MCDB131 culture medium with forskolin (40 μM) and FTY720P (50 nM) as measured via fluorescein isothiocyanate (FITC)-dextran transendothelial permeability assay. [Figure 7] Figures 7A-7B: Efficacy of barrier agonist compounds forskolin and FTY720P in increasing expression of tight junction (TJ) and adherens junction (AJ) proteins in cultured HPAECs 18 hours after treatment with both compounds as measured by flow cytometry. (Figure 7A) Percentage of cells positive for each assayed junction protein. (Figure 7B) Raw trace. [Figure 8] Figures 8A-8B: Efficacy of barrier agonist compounds forskolin and FTY720P in increasing expression of tight junction proteins and adherens junction proteins at the plasma membrane of cultured HPAECs 2 hours (Figure 8A) and 18 hours (Figure 8B) after treatment with both compounds, as measured by immunofluorescence. [Figure 9] Figure 1 shows the synergistic effect of the barrier agonist compound methylprednisolone (MP) in combination with forskolin and fingolimod phosphate on increasing transepithelial electrical resistance (TEER) of cultured HPAECs. Two-way ANOVA with multiple comparisons was performed. **p<0.001 from N=3 independent biological replicates. [Figure 10]10A-B: Effect of barrier agonist compounds on HPAEC proliferation in vitro. (FIG. 10A) Quantification of cell number over time under various treatment conditions. 0 hours after seeding, cells were treated with medium alone or medium supplemented with barrier agonist compounds. (FIG. 10B) Quantification of cell number over time under various treatment conditions. 48 hours after seeding, cells were treated with medium alone or medium supplemented with barrier agonist compounds. Two-way ANOVA with multiple comparisons was performed. p<0.001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The embodiments according to the present disclosure are described more completely below. However, aspects of the present disclosure may be implemented in different forms and should not be construed as being limited to the embodiments shown herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the present invention to those skilled in the art. The terminology used in the description of this specification is intended only to describe specific embodiments and is not intended to be limiting.

[0015] Unless otherwise specified, all terms used herein (including technical and scientific terms) have the same meaning as those generally understood by those skilled in the art to which the present invention belongs. Terms, such as those defined in commonly used dictionaries, should be interpreted to have a meaning consistent with their meaning in the context of this application and related art, and should not be interpreted in an idealized or overly formal sense unless otherwise specified herein. Although not explicitly defined below, such terms should be interpreted according to their general meaning.

[0016] The terminology used in the description of this specification is intended to describe specific embodiments only and is not intended to limit the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will take precedence. Other aspects are set forth in the following claims.

[0017] The practice of the present techniques will employ, unless otherwise indicated, conventional techniques of tissue culture, immunology, molecular biology, microbiology, chemical manipulation, and cell biology, which are within the skill of the art.

[0018] Unless otherwise indicated by context, it is specifically intended that the various features described herein may be used in any combination.Furthermore, the present disclosure also contemplates that in some embodiments, any feature or combination of features set forth herein may be eliminated or omitted.For illustrative purposes, if it is described herein that a complex comprises components A, B, and C (or A, B, and / or C), it is specifically intended that any of A, B, or C, or combinations thereof, alone or in any combination, may be omitted and eliminated.

[0019] Unless expressly stated otherwise, all specified embodiments, features, and terms are intended to include both the described embodiment, feature, or term and biological equivalents thereof.

[0020] All numerical designations, including ranges, e.g., pH, temperature, time, concentration, and molecular weight, are approximations that may be varied (+) or (-) by increments of 1.0 or 0.1, as appropriate, or by variances of + / - 15%, or alternatively 10%, or alternatively 5%, or alternatively 2%. It is understood, although not always explicitly stated, that all numerical designations are preceded by the term "about."

[0021] definition As used in the description of this invention and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0022] The terms "substantially" and "about" are used herein to describe and explain small variations. When used in conjunction with an event or circumstance, the term can refer to when the event or circumstance occurs exactly and when the event or circumstance occurs approximately. When used in conjunction with a numerical value, the term can refer to a variation range of ±10% or less of the numerical value, for example, ±5% or less, ±4% or less, ±3% or less, ±2% or less, ±1% or less, ±0.5% or less, ±0.1% or less, or ±0.05% or less. When describing a first numerical value as being "substantially" or "about" equal to a second numerical value, the term can refer to the first numerical value being within a variation range of ±10% or less of the second numerical value, for example, ±5% or less, ±4% or less, ±3% or less, ±2% or less, ±1% or less, ±0.5% or less, ±0.1% or less, or ±0.05% or less. The terms "acceptable," "effective," or "sufficient," when used to describe the selection of any components, ranges, dosage forms, etc. disclosed herein, mean that the components, ranges, dosage forms, etc. are appropriate for the purpose disclosed.

[0023] Furthermore, amounts, ratios, and other numerical values ​​may be expressed in range format herein.It is understood that such range format is used for convenience and convenience, and should be understood flexibly to include not only the numerical values ​​explicitly specified as the limits of the range, but also all individual numerical values ​​or subranges contained in the range as if each numerical value and subrange were explicitly specified.For example, a ratio range of about 1 to about 200 should be understood to include not only the explicitly stated limits of about 1 and about 200, but also individual ratios such as about 2, about 3, and about 4, and subranges such as about 10 to about 50, about 20 to about 100, etc.

[0024] Similarly, as used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").

[0025] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where the event or circumstance occurs and cases where it does not occur.

[0026] As used herein, the term "barrier agonist compound" refers to any compound that can enhance the endothelial cell vascular barrier, for example as determined by reducing vascular leakage.Barrier agonist compounds can enhance the endothelial cell vascular barrier through one or more overlapping or different mechanisms.As a non-limiting example, barrier agonists can generally enhance the endothelial expression of tight junction proteins and adherens junction proteins, which help regulate the movement of fluids and molecules from the bloodstream to the underlying lung tissue.

[0027] As used herein, the term "complete medium" refers to a cell culture medium optimized for enhancing the vascular barrier of endothelial cells (e.g., human pulmonary artery endothelial cells (HPAEC), human microvascular endothelial cells (HMVEC)). In some cases, the complete medium includes inorganic salts, trace elements, vitamins, amino acids, lipids, carbohydrates, cytokines, growth factors, small molecules, and / or additional proteins, where the ratio of the components relative to each other is optimized for enhancing the vascular barrier. In some embodiments, the complete medium includes 1× Large Vascular Endothelial Supplement (LVES). In some embodiments, the complete medium includes EGF, hydrocortisone, ascorbic acid, heparan sulfate, basic FGF, about 2% FBS, about 2 ng / mL VEGF, and about 30 nM sodium selenite. Exemplary additional proteins include albumin, transferrin, fibronectin, and insulin. Exemplary carbohydrates include glucose. Exemplary inorganic salts include sodium ions, potassium ions, and calcium ions. Exemplary trace elements include zinc, copper, selenium, and tricarboxylic acids. Exemplary amino acids include essential amino acids, such as L-glutamine (e.g., alanyl-l-glutamine or glycyl-l-glutamine), or non-essential amino acids (NEAAs), such as glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, and / or L-serine. Exemplary small molecules include forskolin, fingolimod-phosphate (FTY720P), and methylprednisolone (MP). In some embodiments, the complete medium also contains sodium bicarbonate (NaHCO 3 ), HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), phenol red, antibiotics, and / or β-mercaptoethanol. In some cases, the complete medium is a serum-free medium. In some cases, the complete medium is a xeno-free medium.

[0028] As used herein, the term "endothelial cell" refers to any cell of the endothelium. Normally, endothelial cells form a cell monolayer that lines the surface of all blood vessels and regulates exchange between the bloodstream and the surrounding tissues (Alberts B, Johnson A, Lewis J, et al., Molecular Biology of the Cell. 4 th Edition. Garland Science; 2002). The endothelial cells can be endothelial cells of any organ system. For example, the endothelial cells can be lung endothelial cells or pulmonary endothelial cells. The endothelial cells can be human endothelial cells or non-human endothelial cells. The endothelial cells can be cultured endothelial cells. The endothelial cells can be isolated from organ tissue using any method known in the art. The endothelial cells can be cultured using any method known in the art.

[0029] As used herein, the term "vascular leakage" refers to the movement of fluids through a vascular barrier or membrane. In some embodiments, vascular leakage refers to the extravasation of fluids and molecules from inside the blood vessel into the underlying tissue. In some embodiments, increased vascular leakage reflects increased permeability of the endothelial cell barrier, and decreased vascular leakage reflects decreased permeability of the endothelial cell barrier.

[0030] Compositions for improving endothelial cell barriers - Patents.com Also provided herein are cell culture media compositions for enhancing the vascular barrier of endothelial cells. In some embodiments, cell culture media compositions for enhancing the vascular barrier of cultured endothelial cells are provided.

[0031] In some aspects, the cell culture medium composition for enhancing endothelial cell vascular barrier comprises at least one barrier agonist compound. In some embodiments, the cell culture medium composition for enhancing endothelial cell vascular barrier comprises at least two (i.e., two, three, four, five or more) barrier agonist compounds. Non-limiting examples of barrier agonist compounds include adenylyl cyclase activators, activators of sphingosine-1-phosphate (S1P) receptor internalization, direct or indirect activators of signal transduction enzyme Rac1, direct or indirect inducers of tight junction protein (e.g., ZO-1, JAM-A, claudin-5, and occludin) expression, and direct or indirect inducers of adherens junction protein (e.g., VE-cadherin) expression. In some cases, the cell culture medium is an FBS-based medium, optionally supplemented with at least one barrier agonist compound. In some cases, the cell culture medium is a serum-free medium that is optionally supplemented with one or more barrier agonist compounds. In some cases, the cell culture medium is a minimal medium that is optionally supplemented with one or more barrier agonist compounds. In some cases, the cell culture medium further comprises one or more amino acid supplements (e.g., L-glutamine) and / or antibiotics. In some cases, the cell culture medium composition is used with the method described below for enhancing vascular barrier, such as endothelial cells, for example, pulmonary endothelial cells, human pulmonary artery endothelial cells (HPAEC), or human microvascular endothelial cells (HMVEC).

[0032] In some embodiments, the endothelial cells are lung endothelial cells. In some embodiments, the endothelial cells are pulmonary endothelial cells. In some embodiments, the endothelial cells are human endothelial cells. In some embodiments, the endothelial cells are cultured endothelial cells. In some embodiments, the endothelial cells are human pulmonary artery endothelial cells (HPAEC) or human microvascular endothelial cells (HMVEC).

[0033] In some embodiments of the cell culture medium composition, the adenylyl cyclase activator may be present at a molar concentration of about 1 μM to about 100 μM or any value or subrange therebetween. In some embodiments, the adenylyl cyclase activator may be present at a molar concentration of about 10 μM to about 60 μM or any value or subrange therebetween. In some embodiments, the adenylyl cyclase activator may be present at a molar concentration of about 30 μM to about 50 μM or any value or subrange therebetween. Regarding the concentration of the product, the adenylyl cyclase activator may further be included at a molar concentration of about 30 μM, 31 μM, 32 μM, 33 μM, 34 μM, 35 μM, 36 μM, 37 μM, 38 μM, 39 μM, 40 μM, 41 μM, 42 μM, 43 μM, 44 μM, 45 μM, 46 μM, 47 μM, 48 μM, 49 μM, or 50 μM. In some preferred embodiments, the adenylyl cyclase activator is included at a molar concentration of about 40 μM. In some embodiments, the adenylyl cyclase activator includes any activator that enhances the activity of adenylyl cyclase or increases the production of cyclic adenosine monophosphate (cAMP). In some embodiments, the adenylyl cyclase activator induces the activation of proteins Epac and Rap1, and / or protein kinase A (PKA), thereby inducing rearrangement of the actin cytoskeleton adjacent to the plasma membrane. In some embodiments, the adenylyl cyclase activator increases the expression of adherens junction proteins (e.g., VE-cadherin). In some cases, one or more adenylyl cyclase activators are included in the cell culture medium composition. Non-limiting examples of direct and indirect activators of adenylyl cyclase include forskolin, cholera toxin, prostaglandin E1, norepinephrine (NE), prostaglandin E2, prostaglandin I2, pituitary adenylate cyclase activating polypeptide 1-27 (PACAP1-27), PACAP1-38, and NKH477.

[0034] In some embodiments of the cell culture medium composition, the activator of internalization of the S1P receptor may be present at a molar concentration of about 1 nM to about 100 nM or any value or subrange therebetween.In some embodiments, the activator of internalization of the S1P receptor may be present at a molar concentration of about 10 nM to about 70 nM or any value or subrange therebetween.In some embodiments, the activator of internalization of the S1P receptor may be present at a molar concentration of about 40 nM to about 60 nM or any value or subrange therebetween. With respect to the concentration of the product, the activator of internalization of S1P receptor may further be included at a molar concentration of about 40nM, 41nM, 42nM, 43nM, 44nM, 45nM, 46nM, 47nM, 48nM, 49nM, 50nM, 51nM, 52nM, 53nM, 54nM, 55nM, 56nM, 57nM, 58nM, 59nM, or 60nM. In some preferred embodiments, the activator of internalization of S1P receptor is included at a molar concentration of about 50nM. In some embodiments, the activator of internalization of S1P receptor includes any activator that increases the internalization of S1P receptor. In some embodiments, the activator of internalization of S1P receptor increases the expression of tight junction proteins (e.g., ZO-1, JAM-A, claudin-5, occludin). In some cases, one or more activators of S1P receptor internalization are included in the cell culture medium composition. In some embodiments, the activator of S1P receptor internalization can be fingolimod-phosphate (FTY720P) or S1P.

[0035] In some embodiments, the cell culture medium composition comprises at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor. In some embodiments, the cell culture medium composition comprising at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor comprises the adenylyl cyclase activator at a concentration ranging from about 1 μM to about 100 μM, and the activator of internalization of S1P receptor at a concentration ranging from about 1 nM to about 100 nM. In some preferred embodiments, the cell culture medium composition comprising at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor comprises the adenylyl cyclase activator at a concentration ranging from about 30 μM to about 50 μM, and the activator of internalization of S1P receptor at a concentration ranging from about 40 nM to about 60 nM. In some preferred embodiments, the cell culture medium composition comprising at least one adenylyl cyclase activator and at least one activator of S1P receptor internalization comprises the adenylyl cyclase activator at a concentration of about 40 μM, and the activator of S1P receptor internalization at a concentration of about 50 nM.

[0036] In some embodiments, the cell culture medium composition comprises at least one adenylyl cyclase activator, at least one activator of internalization of S1P receptor, and at least one additional barrier agonist compound. The additional barrier agonist compound may act through a mechanism substantially the same as or different from the mechanism of the at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor. For example, the additional barrier agonist compound may be, but is not limited to, a compound that induces the expression of endothelial adhesion molecules and / or affects the transcriptional regulation of binding proteins. In some embodiments, the cell culture medium composition comprises an adenylyl cyclase activator at a concentration ranging from about 1 μM to about 100 μM, an activator of internalization of S1P receptor at a concentration ranging from about 1 nM to about 100 nM, and at least one additional barrier agonist compound at a concentration ranging from about 0.5 μM to about 50 μM. In some preferred embodiments, the cell culture medium composition comprises an adenylyl cyclase activator at a concentration ranging from about 30 μM to about 50 μM, an activator of internalization of S1P receptor at a concentration ranging from about 40 nM to about 60 nM, and at least one additional barrier agonist compound at a concentration ranging from about 0.5 μM to about 2 μM. In some preferred embodiments, the cell culture medium composition comprises an adenylyl cyclase activator at a concentration of about 40 μM, an activator of internalization of S1P receptor at a concentration of about 50 nM, and at least one additional barrier agonist compound at a concentration of about 1 μM. In some embodiments, the cell culture medium composition comprises forskolin and FTY-720P. In some embodiments, the at least one additional barrier agonist compound is methylprednisolone. In some embodiments, the cell culture medium composition comprises forskolin, FTY-720P, and methylprednisolone.

[0037] In some embodiments of the culture medium composition, fetal bovine serum (FBS) can be at about 1% to about 10% volume concentration (v / v), or any value or subrange therebetween. In certain product concentrations, fetal bovine serum may be included at a volumetric concentration (v / v) of about 1.25%, 1.5%, 1.75%, 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4.75%, 5.0%, 5.25%, 5.5%, 5.75%, 6.0%, 6.25%, 6.5%, 6.75%, 7.0%, 7.25%, 7.5%, 7.75%, 8.0%, 8.25%, 8.5%, 8.75%, 9.0%, 9.25%, 9.5%, 9.75%, or 10.0%. In some cases, FBS is included at a concentration of about 2%.

[0038] In some embodiments of the culture medium composition, the composition comprises a basal medium further supplemented with one or more additional components, such as an adenylyl cyclase activator and an activator of internalization of S1P receptors. In some cases, the basal medium is MCDB131 (Gibco (10372019)) medium. In some cases, the basal medium is HPLM (Gibco (A4899101)) medium. In some embodiments, the basal medium is endothelial cell growth medium 2 (EGM2, PromoCell). In some cases, the culture medium composition comprises L-glutamine (e.g., GlutaMAX™). In some cases, the medium composition comprises about 0.1 μg / mL to about 10,000 μg / mL. In some cases, the medium composition comprises about 0.1 μg / mL to about 10,000 μg / mL. In some cases, the medium composition comprises about 0.1 μg / mL to about 100 μg / mL of an antibiotic. In some embodiments, the media composition comprises about 0.1 μg / mL to about 50 μg / mL of an antibiotic. Non-limiting examples of antibiotics include penicillin, streptomycin, amphotericin, gentamicin, and amphotericin B.

[0039] In some embodiments, the medium composition comprises a basal medium selected from MCDB131 medium and HPLM medium.In some cases, the medium composition further comprises EGF, hydrocortisone, ascorbic acid, heparan sulfate, basic FGF, about 2% FBS, about 2ng / mL VEGF, about 30nM sodium selenite, forskolin, and FTY720P.In some cases, the medium composition further comprises EGF, hydrocortisone, ascorbic acid, heparan sulfate, basic FGF, about 2% FBS, about 2ng / mL VEGF, about 30nM sodium selenite, forskolin, FTY720P, and methylprednisolone (MP).

[0040] Methods for improving endothelial cell barrier - Patents.com Disclosed herein, in certain embodiments, are methods for enhancing the vascular barrier of endothelial cells, including, for example, HPAECs and HMVECs.

[0041] One method to minimize vascular leakage is through increased expression of endothelial cell-cell junction proteins. Endothelial cell-cell junction proteins include, but are not limited to, tight junction (e.g., ZO-1, JAM-A, claudin-5, occludin) proteins and adherens junction (e.g., VE-cadherin) proteins. Conventional endothelial culture methods, particularly endothelial cell culture methods within or on recellularized scaffolds, involve growth in microvascular endothelial cell culture medium MCDB131, which is not specifically designed to reinforce endothelial barriers. In these methods, MCDB131 basal medium is combined with macrovascular endothelial supplement (LVES) to create MCDB complete medium, which is designed to prioritize cell growth over the formation of a stable vascular barrier (see Table 1).

[0042] [Table 1]

[0043] Provided herein is a method for producing endothelial cells, in which the strengthening of vascular barrier is prioritized over cell proliferation.The strengthening of vascular barrier can be prioritized by adding a barrier agonist compound (e.g., forskolin, fingolimod-phosphate (FTY720P), and / or methylprednisolone (MP)) to cell culture medium (e.g., MCDB131 or HPLM).

[0044] The signaling enzyme Rac1 functions as a key mediator in the process of vascular barrier strengthening. Forskolin-induced increase in cAMP leads to Rac1-mediated tightness of the endothelial barrier. Forskolin stimulates the enzyme adenylyl cyclase to generate cyclic adenosine monophosphate (cAMP). cAMP utilizes two major downstream signaling pathways to strengthen the vascular barrier: cAMP directly binds to Epac1, and Epac1 acts through Rap1 to stimulate guanine nucleotide exchange factors (GEFs) to activate Rac1. Alternatively, cAMP can activate PKA, which also leads to activation of Rac1 via GEFs. Activation of Rac1 via Epac1 / Rap1 or PKA enhances the vascular barrier by strengthening the cortical actin cytoskeleton via increased expression of tight junction proteins and adherens junction proteins (e.g., claudins, occludin, VE-cadherin, etc.) (Schegel and Washke, Cell Tissue Res, 2014).

[0045] The phosphorylated and active FTY720 metabolite, FTY720P, induces internalization of sphingosine-1-phosphate (S1P) receptors, which translocate from the plasma membrane to the cytoplasm, causing further cytoskeletal rearrangements and barrier strengthening, in part through increased expression of claudin-5. Furthermore, S1P (and FTY720P) also leads to activation of Rac1 and subsequent vascular barrier tightness.

[0046] Methylprednisolone (MP) is a synthetic anti-inflammatory glucocorticoid. Direct gene targets of this glucocorticoid include tight junctions (occludin, claudin-5) and adherens junctions (VE-cadherin). MP is also an anti-edema drug with a role in fluid resorption, inducing upregulation of aquaporin water channels that increase the water permeability of cell membranes. MP acts by binding to the glucocorticoid receptor (GR) in the cytoplasm. The GC-GR complex translocates to the nucleus, where it stimulates the transcription of binding proteins via GC-responsive elements (GREs).

[0047] In some embodiments, the present disclosure provides a method for culturing endothelial cells with enhanced vascular barrier. In some embodiments, the cultured endothelial cells are lung endothelial cells. In some embodiments, the cultured endothelial cells are pulmonary endothelial cells. In some embodiments, the cultured endothelial cells are human endothelial cells. In some embodiments, the cultured endothelial cells are human pulmonary artery endothelial cells (HPAEC) or human microvascular endothelial cells (HMVEC). The endothelial cells can be cultured by methods known in the art. The endothelial cells can be cultured on two-dimensional or three-dimensional matrices.

[0048] HPAECs are cells derived from human pulmonary artery endothelium. They are adherent and have a cobblestone-like appearance. HPAECs can be characterized by expression of the surface protein markers platelet endothelial cell adhesion molecule (PECAM / CD31) and vascular endothelial cadherin (VE-cadherin / CD144). These cells also express von Willebrand factor (vWF), vascular endothelial growth factor receptor 2 (VEGFR-2 / Flk-1 / KDR), vascular endothelial growth factor 1 (VEGFR1 / Flt-1), and endothelial nitric oxide synthase (eNOS). In vitro functional properties of HPAECs include uptake of acetylated low-density lipoprotein (Ac-LDL) and formation of a lumen.

[0049] In some embodiments, the present disclosure provides a method for producing endothelial cells. In some embodiments, the present disclosure provides a method for producing endothelial cells with enhanced vascular barrier. In some embodiments, the present disclosure provides a method for producing endothelial cells, comprising contacting endothelial cells with at least two barrier agonist compounds. In some embodiments, the present disclosure provides a method for producing endothelial cells, comprising contacting endothelial cells with at least three barrier agonist compounds. In some aspects, such a method comprises culturing endothelial cells in a cell culture medium, wherein contacting endothelial cells with at least two barrier agonist compounds is performed during the culturing step. Generally, when endothelial cells become confluent in culture, endothelial cells may be contacted with barrier agonist compounds. In some embodiments, the endothelial cells may be contacted with a barrier agonist compound when the endothelial cells are about 50%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% confluent in culture.

[0050] In some embodiments, the present disclosure provides a method for producing endothelial cells, comprising contacting endothelial cells with at least one barrier agonist compound. In some aspects, such a method comprises culturing endothelial cells in a cell culture medium, wherein contacting endothelial cells with at least one barrier agonist compound is performed during the culturing step. Generally, endothelial cells may be contacted with a barrier agonist compound when the endothelial cells are confluent in culture. In some embodiments, endothelial cells may be contacted with a barrier agonist compound when the endothelial cells are about 50%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% confluent in culture.

[0051] In some embodiments, the barrier agonist compound may be added directly to the cell culture medium containing the endothelial cells. In some aspects, the barrier agonist compound can be contacted with the endothelial cells by directly adding the barrier agonist compound to the cell culture medium in which the endothelial cells are cultured. In some cases, the barrier agonist compound can be contacted with the endothelial cells by contacting the endothelial cells with the cell culture medium containing the barrier agonist compound.

[0052] In some embodiments, endothelial cells may be contacted with at least one barrier agonist compound for a period of time sufficient to allow endothelial cells to strengthen the vascular barrier. In some embodiments, the period of time sufficient to allow endothelial cells to strengthen the vascular barrier may range from about 1 hour to about 10 days. In some embodiments, the period of time sufficient to allow endothelial cells to strengthen the vascular barrier may be at least 1 hour, at least 2 hours, at least 10 hours, at least 15 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 72 hours, at least 96 hours, at least 100 hours, at least 120 hours, or at least 150 hours or more. In some embodiments, endothelial cells may be subjected to one or more cycles of medium exchange. In some embodiments, endothelial cells may not be subjected to any medium exchange cycles at all. For example, and by way of illustration only, endothelial cells contacted with a barrier agonist compound for 120 hours may be maintained in the same culture medium containing a barrier agonist compound for 120 hours without medium exchange. As another example, for illustrative purposes only, endothelial cells contacted with a barrier agonist compound for 120 hours may be subjected to one, two, three or more cycles of medium exchange over the course of the 120 hour contact period, where each medium exchange cycle includes removing culture medium from the cells and adding fresh medium containing the barrier agonist compound to the cells.

[0053] In some embodiments, the strengthening of vascular barrier is measured and / or characterized by the reduction of vascular leakage. Generally, vascular leakage is the movement of fluid and molecules through vascular barrier, for example, from bloodstream to underlying tissue. Vascular leakage can be assayed by any applicable technique according to the present disclosure. Non-limiting examples of techniques for measuring vascular leakage or quantifying the adhesion of vascular barrier include electrical cell-substrate impedance sensing (ECIS), transendothelial electrical resistance (TEER) measurement, and fluorescein isothiocyanate (FITC)-dextran transendothelial permeability assay.

[0054] In some embodiments, the present disclosure provides a method for producing a transplantable organ using the endothelial cells produced according to the method described herein.Non-limiting examples of transplantable organs include lungs, hearts, kidneys, and livers.In some embodiments, the transplantable organ is a transplantable lung.

[0055] Any type of endothelial cell can be used according to the present disclosure.Non-limiting examples of endothelial cells include human pulmonary vein endothelial cells (HPVEC), human aortic endothelial cells (HAoEC), human coronary artery endothelial cells (HCAEC), human liver sinusoidal endothelial cells (HLSEC), human glomerular endothelial cells (HGEC), and human umbilical vein endothelial cells (HUVEC).In some embodiments, the endothelial cells are selected from the group consisting of human pulmonary artery endothelial cells (HPAEC) and human pulmonary microvascular endothelial cells (HMVEC).

[0056] In some embodiments of the method for producing endothelial cells, the adenylyl cyclase activator can be present at a molar concentration of about 1 μM to about 100 μM or any value or subrange therebetween.In some aspects of the method for producing endothelial cells, the adenylyl cyclase activator can be present at a molar concentration of about 10 μM to about 60 μM or any value or subrange therebetween.In some embodiments, the adenylyl cyclase activator can be present at a molar concentration of about 30 μM to about 50 μM or any value or subrange therebetween. In some embodiments of the method for producing endothelial cells, the adenylyl cyclase activator may further comprise a molar concentration of about 30 μM, 31 μM, 32 μM, 33 μM, 34 μM, 35 μM, 36 μM, 37 μM, 38 μM, 39 μM, 40 μM, 41 μM, 42 μM, 43 μM, 44 μM, 45 μM, 46 μM, 47 μM, 48 μM, 49 μM, or 50 μM. In some preferred embodiments, the adenylyl cyclase activator comprises a molar concentration of about 40 μM. In some embodiments, the adenylyl cyclase activator comprises any activator that enhances the activity of adenylyl cyclase or increases the production of cyclic adenosine monophosphate (cAMP). In some embodiments, the adenylyl cyclase activator induces the activation of proteins Epac and Rap1, thereby inducing rearrangement of the cortical actin cytoskeleton. In some embodiments, the adenylyl cyclase activator increases the expression of adherens junction proteins, such as VE-cadherin. In some cases, one or more adenylyl cyclase activators are included in the cell culture medium composition used in the method of generating endothelial cells. Non-limiting examples of direct and indirect activators of adenylyl cyclase include forskolin, cholera toxin, prostaglandin E1, norepinephrine (NE), prostaglandin E2, prostaglandin I2, pituitary adenylate cyclase activating polypeptide 1-27 (PACAP1-27), PACAP1-38, and NKH477.

[0057] In some embodiments of the method for producing endothelial cells, the activator of internalization of S1P receptors can be present at a molar concentration of about 1 nM to about 100 nM or any value or subrange therebetween.In some aspects, the activator of internalization of S1P receptors can be present at a molar concentration of about 10 nM to about 70 nM or any value or subrange therebetween.In some embodiments of the method for producing endothelial cells, the activator of internalization of S1P receptors can be present at a molar concentration of about 40 nM to about 60 nM or any value or subrange therebetween. In some embodiments of the method of producing endothelial cells, the activator of internalization of S1P receptor may be included at a molar concentration of about 40nM, 41nM, 42nM, 43nM, 44nM, 45nM, 46nM, 47nM, 48nM, 49nM, 50nM, 51nM, 52nM, 53nM, 54nM, 55nM, 56nM, 57nM, 58nM, 59nM, or 60nM. In some preferred embodiments, the activator of internalization of S1P receptor is included at a molar concentration of about 50nM. In some embodiments, the activator of internalization of S1P receptor includes any activator that increases the internalization of S1P receptor. In some embodiments, the activator of internalization of S1P receptor increases the expression of tight junction proteins (e.g., ZO-1, JAM-A, claudin-5, and / or occludin). In some cases, one or more activators of S1P receptor internalization are included in the cell culture medium composition used in the method for producing endothelial cells.In some embodiments, the activator of S1P receptor internalization can be fingolimod-phosphate (FTY720P) or S1P.

[0058] In some embodiments of the method for producing endothelial cells, methylprednisolone (MP) can be present in the culture medium at a molar concentration of about 0.1 μM to about 50 μM or any value or subrange therebetween. In some aspects, methylprednisolone can be present at a molar concentration of about 0.5 μM to about 10 μM or any value or subrange therebetween. In some aspects, methylprednisolone can be present at a molar concentration of about 0.5 μM to about 2 μM or any value or subrange therebetween. In some embodiments of the method for producing endothelial cells, methylprednisolone may be included at a molar concentration of about 0.5 μM, about 0.6 μM, about 0.7 μM, about 0.8 μM, about 0.9 μM, about 1 μM, about 1.1 μM, about 1.2 μM, about 1.3 μM, about 1.4 μM, about 1.5 μM, about 1.6 μM, about 1.7 μM, about 1.8 μM, about 1.9 μM, or about 2 μM. In some preferred embodiments, methylprednisolone is included at a molar concentration of about 1 μM. In some embodiments, methylprednisolone increases the integrity of the vascular barrier, for example, by inducing the expression of adhesion molecules.

[0059] In some embodiments, the method of making endothelial cells comprises contacting endothelial cells with at least two barrier agonist compounds.In some such embodiments, the method of making endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor.In some embodiments, the method of making endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration ranging from about 1 μM to about 100 μM, and at least one activator of internalization of S1P receptor is present at a concentration ranging from about 1 nM to about 100 nM. In some preferred embodiments, the method for producing endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein the at least one adenylyl cyclase activator is present at a concentration ranging from about 30 μM to about 50 μM, and the at least one activator of internalization of S1P receptor is present at a concentration ranging from about 40 nM to about 60 nM. In some preferred embodiments, the method for producing endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein the at least one adenylyl cyclase activator is present at a concentration of about 40 μM, and the at least one activator of internalization of S1P receptor is present at a concentration of about 50 nM.

[0060] In some embodiments, the method of making endothelial cells comprises contacting endothelial cells with at least three barrier agonist compounds.In some such embodiments, the method of making endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor.In some embodiments, the method of making endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration ranging from about 1 μM to about 100 μM, and at least one activator of internalization of S1P receptor is present at a concentration ranging from about 1 nM to about 100 nM. In some preferred embodiments, the method for producing endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein the at least one adenylyl cyclase activator is present at a concentration ranging from about 30 μM to about 50 μM, and the at least one activator of internalization of S1P receptor is present at a concentration ranging from about 40 nM to about 60 nM. In some preferred embodiments, the method for producing endothelial cells comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein the at least one adenylyl cyclase activator is present at a concentration of about 40 μM, and the at least one activator of internalization of S1P receptor is present at a concentration of about 50 nM. In some embodiments, the method for producing endothelial cells may include contacting endothelial cells with at least three (i.e., three, four, five, six or more) barrier agonist compounds, where the at least three barrier agonist compounds include forskolin, fingolimod-phosphate, and methylprednisolone (MP). In some such embodiments of the method for producing endothelial cells, forskolin may be present at a concentration of about 30 μM to about 50 μM. Preferably, forskolin may be present at a concentration of about 40 μM. In some embodiments, fingolimod-phosphate may be present at a concentration of about 5 nM to about 50 nM.Preferably, fingolimod-phosphate can be present at a concentration of about 50nM. In some preferred embodiments, forskolin can be present at a concentration of about 40μM, and fingolimod-phosphate can be present at a concentration of about 50nM. In some preferred embodiments, methylprednisolone can be present at a concentration of about 0.5μM to about 2μM. In some preferred embodiments, methylprednisolone can be present at a concentration of about 1μM. In some preferred embodiments, forskolin can be present at a concentration of about 40μM, fingolimod-phosphate can be present at a concentration of about 50nM, and methylprednisolone can be present at a concentration of about 1μM.

[0061] The present disclosure provides an improvement to a method for producing lung tissue from cultured endothelial cells in cell culture medium. In some embodiments, the improvement to the method for producing lung tissue from cultured endothelial cells in cell culture medium includes (i) contacting the cultured endothelial cells with at least one barrier agonist compound, and (ii) maintaining the endothelial cells in cell culture medium for a period of time sufficient to allow the endothelial cells to strengthen the vascular barrier, wherein the strengthening of the vascular barrier is characterized by a reduction in vascular leakage. In some embodiments, the improvement to the method for producing lung tissue from cultured endothelial cells in cell culture medium includes (i) contacting the cultured endothelial cells with at least two barrier agonist compounds, and (ii) maintaining the endothelial cells in cell culture medium for a period of time sufficient to allow the endothelial cells to strengthen the vascular barrier, wherein the strengthening of the vascular barrier is characterized by a reduction in vascular leakage.

[0062] In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, adenylyl cyclase activator can be present at a molar concentration of about 1 μM to about 100 μM or any value or subrange therebetween.In some aspects of the method of making endothelial cells, adenylyl cyclase activator can be present at a molar concentration of about 10 μM to about 60 μM or any value or subrange therebetween.In some such embodiments, adenylyl cyclase activator can be present at a molar concentration of about 30 μM to about 50 μM or any value or subrange therebetween. In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, the adenylyl cyclase activator may further comprise at a molar concentration of about 30 μM, 31 μM, 32 μM, 33 μM, 34 μM, 35 μM, 36 μM, 37 μM, 38 μM, 39 μM, 40 μM, 41 μM, 42 μM, 43 μM, 44 μM, 45 μM, 46 μM, 47 μM, 48 μM, 49 μM, or 50 μM. In some preferred embodiments, the adenylyl cyclase activator comprises at a molar concentration of about 40 μM. In some embodiments, the adenylyl cyclase activator comprises any activator that enhances the activity of adenylyl cyclase or increases the production of cyclic adenosine monophosphate (cAMP). In some embodiments, the adenylyl cyclase activator induces the activation of proteins Epac and Rap1, and / or PKA, thereby inducing rearrangement of the actin cytoskeleton adjacent to the plasma membrane. In some embodiments, the adenylyl cyclase activator increases the expression of adherens junction proteins (e.g., VE-cadherin). In some cases, one or more adenylyl cyclase activators are included in the cell culture medium composition used in the method of generating lung tissue from cultured endothelial cells in cell culture medium. Non-limiting examples of direct and indirect activators of adenylyl cyclase include forskolin, cholera toxin, prostaglandin E1, norepinephrine (NE), prostaglandin E2, prostaglandin I2, pituitary adenylate cyclase activating polypeptide 1-27 (PACAP1-27), PACAP1-38, and NKH477.

[0063] In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, the activator of internalization of S1P receptors can be present at a molar concentration of about 1 nM to about 100 nM or any value or subrange therebetween.In some such embodiments, the activator of internalization of S1P receptors can be present at a molar concentration of about 10 nM to about 70 nM or any value or subrange therebetween.In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, the activator of internalization of S1P receptors can be present at a molar concentration of about 40 nM to about 60 nM or any value or subrange therebetween. In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, the activator of internalization of S1P receptor may be included at a molar concentration of about 40nM, 41nM, 42nM, 43nM, 44nM, 45nM, 46nM, 47nM, 48nM, 49nM, 50nM, 51nM, 52nM, 53nM, 54nM, 55nM, 56nM, 57nM, 58nM, 59nM or 60nM.In some preferred embodiments, the activator of internalization of S1P receptor is included at a molar concentration of about 50nM.In some embodiments, the activator of internalization of S1P receptor includes any activator that increases the internalization of S1P receptor. In some embodiments, the activator of S1P receptor internalization increases the expression of tight junction proteins (e.g., ZO-1, JAM-A, claudin-5, and / or occludin). In some cases, one or more activators of S1P receptor internalization are included in a cell culture medium composition used in a method of producing lung tissue from cultured endothelial cells in a cell culture medium. In some aspects, the activator of S1P receptor internalization can be fingolimod-phosphate (FTY720P) or S1P.

[0064] In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, methylprednisolone (MP) can be present in the culture medium at a molar concentration of about 0.1 μM to about 50 μM or any value or subrange therebetween.In some aspects, methylprednisolone can be present at a molar concentration of about 0.5 μM to about 10 μM or any value or subrange therebetween.In some aspects, methylprednisolone can be present at a molar concentration of about 0.5 μM to about 2 μM or any value or subrange therebetween. In some embodiments of the method for producing endothelial cells, methylprednisolone may be included at a molar concentration of about 0.5 μM, about 0.6 μM, about 0.7 μM, about 0.8 μM, about 0.9 μM, about 1 μM, about 1.1 μM, about 1.2 μM, about 1.3 μM, about 1.4 μM, about 1.5 μM, about 1.6 μM, about 1.7 μM, about 1.8 μM, about 1.9 μM, or about 2 μM. In some preferred embodiments, methylprednisolone is included at a molar concentration of about 1 μM. In some embodiments, methylprednisolone increases the integrity of the vascular barrier, for example, by inducing the expression of adhesion molecules.

[0065] In some embodiments, the method of preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least two barrier agonist compounds.In some such embodiments, the method of preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor.In some embodiments, the method of preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration ranging from about 1 μM to about 100 μM, and at least one activator of internalization of S1P receptor is present at a concentration ranging from about 1 nM to about 100 nM. In some preferred embodiments, the method for preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration ranging from about 30 μM to about 50 μM, and at least one activator of internalization of S1P receptor is present at a concentration ranging from about 40 nM to about 60 nM. In some preferred embodiments, the method for preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration of about 40 μM, and at least one activator of internalization of S1P receptor is present at a concentration of about 50 nM.

[0066] In some embodiments, the method of preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least three barrier agonist compounds.In some such embodiments, the method of preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor.In some embodiments, the method of preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration ranging from about 1 μM to about 100 μM, and at least one activator of internalization of S1P receptor is present at a concentration ranging from about 1 nM to about 100 nM. In some preferred embodiments, the method for preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration ranging from about 30 μM to about 50 μM, and at least one activator of internalization of S1P receptor is present at a concentration ranging from about 40 nM to about 60 nM. In some preferred embodiments, the method for preparing lung tissue from cultured endothelial cells in cell culture medium comprises contacting endothelial cells with at least one adenylyl cyclase activator and at least one activator of internalization of S1P receptor, wherein at least one adenylyl cyclase activator is present at a concentration of about 40 μM, and at least one activator of internalization of S1P receptor is present at a concentration of about 50 nM. In some embodiments, a method of producing lung tissue from cultured endothelial cells in cell culture medium may include contacting endothelial cells with at least three (i.e., three, four, five, six, or more) barrier agonist compounds, where the at least three barrier agonist compounds include forskolin, fingolimod-phosphate, and methylprednisolone (MP).In some such embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, forskolin can be present at a concentration of about 30 μM to about 50 μM. Preferably, forskolin can be present at a concentration of about 40 μM. In some embodiments, fingolimod-phosphate can be present at a concentration of about 5 nM to about 50 nM. Preferably, fingolimod-phosphate can be present at a concentration of about 50 nM. In some preferred embodiments, forskolin can be present at a concentration of about 40 μM, and fingolimod-phosphate can be present at a concentration of about 50 nM. In some embodiments, methylprednisolone can be present at a concentration of about 0.5 μM to about 2 μM. In some preferred embodiments, methylprednisolone can be present at a concentration of about 1 μM. In some preferred embodiments, forskolin may be present at a concentration of about 40 μM, fingolimod-phosphate may be present at a concentration of about 50 nM, and methylprednisolone may be present at a concentration of about 1 μM.

[0067] In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, the endothelial cells may be exposed to at least one barrier agonist compound for a period of time sufficient to allow the endothelial cells to strengthen the vascular barrier. In some embodiments of the method of making lung tissue from cultured endothelial cells in cell culture medium, the period of time sufficient to allow the endothelial cells to strengthen the vascular barrier may range from about 1 hour to about 10 days. In some embodiments, the period of time sufficient to allow the endothelial cells to strengthen the vascular barrier may be at least 1 hour, at least 2 hours, at least 10 hours, at least 15 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 72 hours, at least 96 hours, at least 100 hours, at least 120 hours, or at least 150 hours, or more. In some such embodiments, the endothelial cells may be subjected to one or more cycles of medium exchange. In some embodiments, the endothelial cells may not be subjected to any medium exchange cycles at all. For example, and by way of illustration only, in a method of producing lung tissue from cultured endothelial cells in cell culture medium, endothelial cells contacted with a barrier agonist compound for 120 hours may be maintained in the same culture medium containing the barrier agonist compound for 120 hours without medium changes. As another example, and by way of illustration only, in a method of producing lung tissue from cultured endothelial cells in cell culture medium, endothelial cells contacted with a barrier agonist compound for 120 hours may be subjected to one, two, three or more cycles of medium changes over the course of the 120 hour contact period, where each medium change cycle includes removing the culture medium from the cells and adding fresh medium containing the barrier agonist compound to the cells. EXAMPLES

[0068] These examples are provided for illustrative purposes only and are not intended to limit the scope of the claims provided herein.

[0069] [Example 1] Endothelial cell barrier-enhancing compounds are functional in multiple different culture media Culture medium To determine whether the barrier agonist compounds could exert vascular barrier enhancing effects in multiple types of cell culture media, different cell culture media were tested. In one assay, two separate cell culture media were tested: 1) MCDB131 complete medium: MCDB131 basal medium supplemented with 1x large vessel endothelial supplement (LVES), and 2) HPLM complete medium: human plasma-like medium (HPLM) supplemented with 1x LVES. The components of each complete medium are listed in Table 1.

[0070] protocol Human pulmonary artery endothelial cells (HPAECs) were cultured in either MCDB131 complete medium or HPLM complete medium (where complete medium contains 1x LVES as defined in Table 1) until confluent. A frozen vial of cells was thawed using a 37 °C water bath. Cells were cultured at 2,000–5,000 cells / cm. 2 Cells were seeded into T75 flasks at a cell density between 0.01 and 0.05% and cultured in complete medium (i.e., MCDB131 complete medium or HPLM complete medium). Cells were incubated at 37°C, 20% O 2 , 5% CO 2 The cells were maintained in a 200-mL incubator at 4°C for 12 h. Cell growth was monitored and the medium was changed every 48 h (i.e., on days 3, 5, 7, etc. of culture).

[0071] Once confluent, cells were treated with or without barrier agonists (40 μM forskolin and 50 nM fingolimod-phosphate (FTY720P)) and assayed for changes in barrier function using the xCELLigence platform (Electrical Cell-Substrate Impedance Sensing (ECIS)) system. Briefly, xCELLigence supported 96-well plates (ACEA Biosciences, E-Plate96PET, Cat. No. 00300600910) were prepared according to the manufacturer's protocol, and then plates were seeded with approximately 6,600 cells / well (corresponding to approximately 20,000 cells / mL). ECIS measurements were obtained at the desired time points. Culture medium was changed daily over the course of the experiment.

[0072] Electrical cell-substrate impedance sensing (ECIS) results after 15 hours, 48 ​​hours, and 5 days of barrier agonist treatment. Higher impedance values ​​indicate tighter endothelial barrier. All results were normalized to pre-treatment impedance levels. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison post-hoc test.

[0073] result As shown graphically in Figures 1A and 1B, the barrier agonist compounds tested were effective in enhancing the impedance of HPAECs cultured in MCDB131 complete medium (Figure 1A) and HPLM complete medium (Figure 1A) at all time points tested. These data suggest that the barrier agonist compounds are compatible with and effective in multiple different types of cell culture media.

[0074] [Example 2] Optimization of forskolin concentration for enhancing vascular barrier in cultured endothelial cells To determine the concentration of forskolin that maximizes the observed endothelial cell barrier adhesion effect, multiple concentrations of forskolin were tested in three separate experiments.

[0075] Experiment 1 Human microvascular endothelial cells (HMVEC obtained from PromoCell, PC) were cultured in MCDB131 complete medium until confluent as described in Example 1. Once confluent, cells were treated with forskolin (10 μM or 40 μM) or not treated (control). ECIS results were obtained at 15 hours, 48 ​​hours, and 5 days (100 hours) of barrier agonist treatment.

[0076] result As shown graphically in Figures 2A and 2B, 40 μM forskolin induced a greater enhancement of vascular barrier strength than 10 μM forskolin or untreated controls.

[0077] Experiment 2 Human microvascular endothelial cells (HMVEC obtained from Cell Applications, CA) were cultured in MCDB131 complete medium until confluent. Once confluent, cells were treated with forskolin (10 μM or 40 μM) or not treated (control). ECIS results were obtained after 15 hours, 48 ​​hours, and 5 days (100 hours) of barrier agonist treatment.

[0078] result As shown graphically in Figures 3A and 3B, 40 μM forskolin induced a greater enhancement of vascular barrier strength than 10 μM forskolin or untreated controls. These data, in light of the results of Experiment 1 and Example 1 of this Example, indicate that forskolin exerts a vascular barrier strengthening effect in multiple different types of endothelial cells.

[0079] Experiment 3 Human pulmonary artery endothelial cells (HPAEC obtained from ATCC) were cultured in MCDB131 complete medium until confluent. Once confluent, cells were treated with forskolin (40 μM or 60 μM) or not treated (control). ECIS results were obtained after 15 hours, 48 ​​hours, and 5 days (100 hours) of barrier agonist treatment.

[0080] result As shown graphically in Figures 4A and 4B, 40 μM forskolin induced a greater enhancement of vascular barrier strength than 60 μM forskolin or untreated controls. These data indicate that forskolin exerts its vascular barrier-strengthening effects in multiple different types of endothelial cells and that its vascular barrier-strengthening effects occur optimally when forskolin is present within a finite range of concentrations.

[0081] [Example 3] Optimization of FTY720P concentration for enhancing vascular barrier in cultured endothelial cells To determine the concentration of FTY720P that maximizes the observed endothelial cell barrier adhesion effect, multiple concentrations of FTY720P were tested.

[0082] Experiment 1 Human pulmonary artery endothelial cells (HPAEC obtained from ATCC) were cultured in MCDB131 complete medium until confluent. Once confluent, cells were treated with forskolin (40 μM), forskolin (40 μM) + FTY720P (50 nM), forskolin (40 μM) + FTY720P (5 nM), or not treated (control). ECIS results were obtained after 15 h, 48 h, and 5 days (120 h) of barrier agonist treatment.

[0083] result As shown graphically in Figure 5, forskolin (40 μM) + FTY720P (50 nM) induced a greater enhancement of vascular barrier strength than forskolin (40 μM) alone, forskolin (40 μM) + FTY720P (5 nM), and untreated controls. These data indicate that FTY720P (50 nM) in combination with forskolin can enhance vascular barrier strengthening of endothelial cells and that this effect is concentration dependent.

[0084] Experiment 2 Human pulmonary artery endothelial cells (HPAEC) were cultured in MCDB131 complete medium on semipermeable collagen-treated membranes until confluent. Once confluent, cells were treated with or without barrier agonists (40 μM forskolin and 50 nM fingolimod-phosphate (FTY720P)) for 18 h and assayed for changes in barrier function using a fluorescein isothiocyanate (FITC)-dextran transendothelial permeability assay. After overnight (18 h) incubation of cultured HPAEC in MCDB131 with or without barrier agonist compounds (as above), cells were incubated in FITC-dextran for 20, 40, or 120 min. After incubation, the levels of FITC-dextran in the underlying medium (i.e., the levels of FITC-dextran that had crossed the endothelial cell monolayer and the underlying semipermeable membrane) were quantified using a fluorescence plate reader with an excitation filter of 485 nm and an emission filter of 535 nm.

[0085] result As shown graphically in Figures 6A-C, forskolin (40 μM) + FTY720P (50 nM) induced a greater enhancement of vascular barrier strength (as measured by a reduction in the amount of FITC-dextran passing through the endothelial cell monolayer to the underlying medium) than that seen in untreated controls, measured after 20 (Figure 6A), 40 (Figure 6B), and 120 minutes (Figure 6C) of incubation with FITC-dextran. Small dots in each plot represent individual wells tested. Statistical analysis was performed using unpaired t-tests. These data provide orthogonal support for the ECIS-based findings in Experiment 1 of Example 3 above.

[0086] [Example 4] Forskolin and FTY720P increase the expression of tight junction proteins and adherens junction proteins at cell-cell junctions in HPAECs This example demonstrates the effectiveness of forskolin and FTY720P in enhancing the expression of tight and adherens junction proteins in cultured endothelial cells.

[0087] protocol Flow cytometric evaluation Human pulmonary artery endothelial cells (HPAECs) were cultured in MCDB131 complete medium (where complete medium contains 1x LVES as defined in Table 1) until confluent. Once confluent, cells were treated with or without barrier agonists (40 μM forskolin and 50 nM fingolimod-phosphate (FTY720P)) for 18 h. After treatment, HPAECs were fixed without permeabilization to protect junctional proteins and stained as indicated. Flow cytometry analysis was performed to quantify the difference in expression of tight junction proteins and adherens junction proteins.

[0088] Evaluation by immunofluorescence staining Human pulmonary artery endothelial cells (HPAECs) were cultured in MCDB131 complete medium (where complete medium contains 1x LVES as defined in Table 1) until confluent. Once confluent, cells were treated with or without barrier agonists (40 μM forskolin and 50 nM fingolimod-phosphate (FTY720P)) for 2 or 18 h and assayed for changes in barrier function. Immunofluorescence staining of tight junction and adherens junction markers (expressed on HPAECs) was performed using antibodies appropriate for immunofluorescence.

[0089] result As shown graphically in Figures 7A and 7B, the barrier agonist compounds tested were effective in increasing the expression of tight and adherens junction proteins in cultured HPAECs as measured by flow cytometry. Quantitation of cells positive for individual binding markers using the same gating between treatment and control is summarized in Figure 7A. Raw data is summarized in Figure 7B. A shift to the right or up of the curve indicates the presence of more binding proteins.

[0090] As shown in Figures 8A and 8B, the barrier agonist compounds tested (40 μM forskolin and 50 nM fingolimod-phosphate (FTY720P)) were effective in increasing the expression of tight junction (ZO-1, claudin-5, and JAM-A) and adherens junction (VE-cadherin) proteins at the plasma membrane of cultured HPAECs as measured by immunofluorescence 2 hours (Figure 8A) and 18 hours (Figure 8B) after treatment with the barrier agonist compounds.

[0091] [Example 5] Forskolin, FTY720P, and methylprednisolone synergistically increase transepithelial electrical resistance of cultured HPAECs This example demonstrates the synergistic effect of combining the barrier agonist compound methylprednisolone (MP) with forskolin and fingolimodrin acid to increase the transepithelial electrical resistance (TEER) of cultured HPAEC obtained from ATCC.

[0092] TEER rating Barrier agonist treatment was initiated on day 2 (48 hours) and maintained throughout the remainder of the culture. Cells were subjected to TEER analysis using an EVOM™ Manual TEER meter (EVOM 3 Instrument, an epithelial volt / ohm meter) according to the manufacturer's protocol (EVOM™ Manual TEER meter: Quick Start Guide, World Precision Instruments, incorporated herein by reference in its entirety). TEER measurements were obtained 24 hours, 48 ​​hours, and 120 hours after barrier agonist treatment in MCDB131 culture medium. Barrier agonist compounds were provided at the following concentrations when administered to the cultures: forskolin (40 μM), FTY720-P (50 nM), methylprednisolone (1 μM).

[0093] result As shown in Figure 9, methylprednisolone treatment significantly increased the TEER of cultured cells compared to cells cultured without any barrier agonist compound. Methylprednisolone alone did not increase TEER to a greater extent than was seen after treatment with forskolin and FTY720-P, but the combination of methylprednisolone, forskolin, and FTY720-P produced a synergistic increase in TEER to a greater extent than after treatment with forskolin and FTY720-P.

[0094] [Example 6] Barrier agonist compounds regulate proliferation of HPAECs This example shows that endothelial cell proliferation is reduced when the cells are cultured in the presence of forskolin (40 μM) and that proliferation is not reduced when the cells are cultured with FTY720-P or MP.

[0095] protocol HPAECs were cultured at low initial confluency (3000–5000 cells / cm 2) to study their proliferation on culture dishes coated with type I collagen. Barrier agonists were added at 0 h (Figure 10A) or 48 h (Figure 10B) and maintained throughout the remainder of the culture. Barrier agonist compounds were added at the following concentrations when added to the culture medium (MCDB131): forskolin (40 μM), FTY720-P (50 nM), methylprednisolone (1 μM). Cell numbers were measured via individual quantification of nuclei stained with Hoechst dye and imaged on a Celigo Imaging Cytometer (Nexcelom Bioscience).

[0096] result As shown in Figure 10A, cells treated with forskolin showed significantly lower endothelial cell proliferation than cells treated with FTY720-P or cells that received no treatment, and as shown in Figure 10B, cells treated with one or more barrier agonist compounds, including forskolin, showed significantly lower endothelial cell proliferation than the groups without the compound (untreated or methylprednisolone only).

[0097] These examples are provided for illustrative purposes only and are not intended to limit the scope of the claims provided herein.

[0098] While certain particular embodiments have been illustrated and described, it is understood that changes and modifications can be made therein in accordance with ordinary skill in the art without departing from the technology in its broader aspects as defined in the following claims.

[0099] The embodiments illustratively described herein may be suitably implemented in the absence of any element or elements, or limitation or limitations not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like, are to be interpreted broadly and without limitation. Furthermore, the terms and expressions used herein are used as terms of description, not as terms of limitation, and the use of such terms and expressions is not intended to exclude any equivalents of the features shown and described or portions thereof, but is recognized to allow various modifications within the scope of the claimed technology. Furthermore, the expression "consisting essentially of" is understood to include the elements specifically recited, as well as additional elements that do not materially affect the basic and novel characteristics of the claimed technology. The expression "consisting of" excludes any elements not specified.

[0100] The present disclosure is not limited with respect to the specific embodiments described in this application. As will be apparent to those skilled in the art, many modifications and variations can be made without departing from the spirit and scope thereof. In addition to those recited herein, functionally equivalent methods and compositions within the scope of the present disclosure will be apparent to those skilled in the art from the foregoing description. Such modifications and variations are intended to be included within the scope of the appended claims. The present disclosure is limited only by the terms of the appended claims, together with the full scope of equivalents that are the subject matter of such claims thereto. It is understood that the present disclosure is not limited to specific methods, reagents, compounds, or compositions, which may of course vary. It is also understood that the terminology used herein is for the purpose of describing specific embodiments only, and is not intended to be limiting.

[0101] Moreover, when features or aspects of the disclosure are described in terms of a Markush group, those skilled in the art will recognize that the disclosure is also thereby described with respect to any individual members or subgroups of members of the Markush group.

[0102] As will be understood by those skilled in the art, for any and all purposes, particularly with respect to the provision of description requirements, all ranges disclosed herein encompass any and all possible subranges and combinations of these subranges, including the endpoints. Any recited range is fully descriptive, and it can be easily recognized that the range can be divided into at least two, three, four, five, ten, etc. As a non-limiting example, each range discussed herein can be easily divided into a lower third, a middle third, an upper third, etc. As will also be understood by those skilled in the art, all terms such as "up to," "at least," "greater than," "less than," etc. refer to a range that includes the recited numerical value and can be subsequently divided into subranges as described above. Finally, as will be understood by those skilled in the art, a range includes each individual member.

[0103] All publications, patent applications, issued patents, and other documents cited herein are incorporated by reference as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions contained in documents incorporated by reference are excluded to the extent that they conflict with definitions in this disclosure.

[0104] Other embodiments are set forth in the following claims.

Claims

1. A method of producing an endothelial cell comprising the step of contacting an endothelial cell with at least two barrier agonist compounds.

2. 2. The method of claim 1, further comprising culturing the endothelial cells in cell culture medium, wherein contacting the endothelial cells with at least two barrier agonist compounds occurs during the culturing step.

3. 2. The method of claim 1, wherein the step of contacting the endothelial cells with at least two barrier agonist compounds is performed for a period of time sufficient to allow the endothelial cells to strengthen the vascular barrier.

4. The method of claim 3, wherein the strengthening of the vascular barrier is determined by a reduction in vascular leakage.

5. The method of claim 1 , wherein the endothelial cells are lung endothelial cells.

6. 6. The method of claim 5, further comprising generating a transplantable lung with endothelial cells.

7. 2. The method of claim 1, wherein the endothelial cells are selected from the group consisting of human pulmonary artery endothelial cells and human pulmonary microvascular endothelial cells.

8. 2. The method of claim 1, wherein the at least two barrier agonist compounds comprise one or more compounds that promote increased expression of endothelial cell-cell junctions, promote increased production of cyclic adenosine monophosphate (cAMP), promote internalization of sphingosine-1-phosphate (S1P) receptors, promote increased production of adherens junction proteins, or promote increased production of tight junction proteins.

9. 2. The method of claim 1, wherein the at least two barrier agonist compounds comprise forskolin and fingolimod-phosphate.

10. 2. The method of claim 1, wherein the contacting step comprises contacting the endothelial cells with forskolin at a concentration of about 30 μM to about 50 μM.

11. 2. The method of claim 1, wherein the contacting step comprises contacting the endothelial cells with forskolin at a concentration of about 40 μM.

12. The method of claim 11, wherein the contacting step further comprises contacting the endothelial cells with fingolimod-phosphate at a concentration of about 50 nM.

13. 2. The method of claim 1, wherein the contacting step comprises contacting the endothelial cells with forskolin at a concentration of about 40 μM and fingolimod-phosphate at a concentration of about 50 nM.

14. 1. A method for producing lung tissue from cultured endothelial cells in a cell culture medium, the improvement comprising: (i) contacting cultured endothelial cells with at least two barrier agonist compounds; and (ii) maintaining the endothelial cells in the cell culture medium for a period of time sufficient to allow the endothelial cells to reinforce the vascular barrier. Including, The method, wherein the strengthening of the vascular barrier is characterized by a reduction in vascular leakage.

15. 15. The method of claim 14, wherein the at least two barrier agonist compounds comprise forskolin and fingolimod-phosphate.

16. 16. The method of claim 15, wherein after the contacting step, forskolin is present in the cell culture medium at a concentration of about 30 μM to about 50 μM.

17. 16. The method of claim 15, wherein after the contacting step, forskolin is present in the cell culture medium at a concentration of about 40 μM.

18. 16. The method of claim 15, wherein after the contacting step, forskolin is present in the cell culture medium at a concentration of about 40 μM and fingolimod-phosphate is present in the cell culture medium at a concentration ranging from about 5 nM to about 50 nM.

19. 16. The method of claim 15, wherein after the contacting step, forskolin is present in the cell culture medium at a concentration of about 40 μM and fingolimod-phosphate is present in the cell culture medium at a concentration of about 50 nM.

20. A cell culture medium comprising at least two barrier agonist compounds, said at least two barrier agonist compounds comprising forskolin and fingolimod-phosphate.

21. 10. The method of claim 9, wherein the barrier agonist compound further comprises methylprednisolone.

22. 21. The cell culture medium of claim 20, further comprising methylprednisolone.